Lexicon Pharmaceuticals’ (LXRX) “Market Perform” Rating Reiterated at Leerink Partners
Leerink Partners reiterated their market perform rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX – Free Report) in a research report report published on Tuesday,Benzinga reports. The brokerage currently has a $1.00 price objective on the biopharmaceutical company’s stock. Other equities research analysts also recently issued reports about the company. Needham & Company LLC reaffirmed a […]
Leerink Partners reiterated their market perform rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX – Free Report) in a research report report published on Tuesday,Benzinga reports. The brokerage currently has a $1.00 price objective on the biopharmaceutical company’s stock. Other equities research analysts also recently issued reports about the company. Needham & Company LLC reaffirmed a […]
